Amerigo Scientific Launches Cost-Effective GalNAc (TEG)-CPG Reagent to Empower Nucleic Acid Therapeutics

More from Amerigo Scientific

  • Amerigo Scientific Launches Ultra Low Temperature Freezers (-40\u00b0C to -86\u00b0C) for Lab Sample Storage
    1 comment, 0 likes
  • Amerigo Scientific Updates Its Laboratory Incubators with More Advanced Features
    1 comment, 0 likes
  • Amerigo Scientific Adds Viral Transport Medium CDC Protocol to Its Distribution List
    1 comment, 0 likes

More in Politics

  • Norton antivirus account login
    31 comments, 144,782 views
  • Liquidity Locking Made Easy
    10 comments, 83,095 views
  • Ang jili178 login ay nagdudulot sa iyo ng mga laro ng slot at karanasan sa laro ng soccer
    2 comments, 46,576 views

Related Blogs

  • Stream: Path of Exile-Finish the build
    0 comments, 0 likes
  • Know Construction Procedure of Pvc Furniture Board
    0 comments, 0 likes
  • About The Characteristics Of Carbon Steel Rivet Nut
    0 comments, 0 likes

Archives

Social Share

Amerigo Scientific Launches Cost-Effective GalNAc (TEG)-CPG Reagent to Empower Nucleic Acid Therapeutics

Posted By Amerigo Scientific     June 27, 2023    

Body

Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, recently announced the launch of its cost-effective GalNAc (TEG)-CPG reagent to empower the development of nucleic acid therapeutics. This reagent is used to synthesize oligonucleotide-GalNAc conjugates.

 

Asialoglycoprotein receptor (ASGPR) is the ideal target for the delivery of therapeutic oligonucleotides to the liver due to its tissue specificity, high expression levels, rapid internalization, and turnover. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with ASGPR. By conjugating it directly to the oligonucleotides or decorating it to a certain delivery system as a targeting moiety, GalNAc has achieved compelling success in the development of nucleic acid therapeutics.

 

Oligonucleotides containing GalNAc can be deprotected using standard procedures during which the acetyl protecting groups on the GalNAc group are removed. Much experimental work has shown that GalNAc CPG is fully compatible with the synthesis of the siRNA-GalNAc conjugate. And the use of oligonucleotide glycoconjugates has led to significant advances in therapeutic delivery as evidenced by the work of researchers using the GalNAc (TEG)-CPG reagents.

 

Amerigo Scientific’s GalNAc (TEG)-CPG can be supplied with pore sizes of 500 Å and 1000 Å. Due to space reasons, the pore size of 1000 Å is suitable for the synthesis of oligonucleotide-GalNAc conjugates with long oligonucleotides, while the pore size of 500 Å is suitable for the synthesis of oligonucleotide-GalNAc conjugates with short oligonucleotides. Depending on the desired oligonucleotide sequence length of clients, different pore sizes are available to facilitate the synthesis and development of oligonucleotide drugs. More important, Amerigo Scientific assures its customers of the high quality of products as well as competitive prices for a wide range of widespread reagents.

 

Other reagents for GalNAc conjugate technology are available under request. Additionally, Amerigo Scientific offers a collection of building blocks, modified nucleoside derivatives, intermediates and other reagents that meet the oligo synthesis or nucleic acids synthesis needs.

 

About Amerigo Scientific

Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation to all companies and institutions in the branch of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers’ questions or concerns and are always ready to provide individualized customer service of high standards.

Comments

1 comment
  • Shcherbak Nazar
    Shcherbak Nazar  · December 12, 2023
    Amerigo Scientific's introduction of the cost-effective GalNAc (TEG)-CPG reagent represents a significant stride in nucleic acid therapeutics. The article adeptly outlines its potential to make treatments more accessible and efficient. This innovation...  more